NASDAQ: APLTApplied Therapeutics Inc Stock
$0.52-0.03 (-5.45%)
Updated Mar 18, 2025
APLT Price
$0.52
Fair Value Price
$1.20
Market Cap
$60.62M
52 Week Low
$0.43
52 Week High
$10.62
P/E
-0.36x
P/B
10.29x
P/S
-5,814.87x
PEG
N/A
Dividend Yield
N/A
Revenue
-$211.00k
Earnings
-$187.31M
Gross Margin
100%
Operating Margin
88,772.51%
Profit Margin
88,772.5%
Debt to Equity
17.09
Operating Cash Flow
-$82M
Beta
1.14
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
APLT Overview
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APLT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APLT
Ranked#379 of 482
Ranked#379 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.35 | A | |
| $139.51 | A | |
| $7.87 | A |
Be the first to know about important APLT news, forecast changes, insider trades & much more!
APLT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APLT ($0.52) is undervalued by 56.59% relative to our estimate of its Fair Value price of $1.20 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APLT ($0.52) is significantly undervalued by 56.59% relative to our estimate of its Fair Value price of $1.20 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
APLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APLT due diligence checks available for Premium users.
Valuation
APLT fair value
Fair Value of APLT stock based on Discounted Cash Flow (DCF)
Price
$0.52
Fair Value
$1.20
Undervalued by
56.67%
APLT ($0.52) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APLT ($0.52) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
-110.15x
Market
30.9x
APLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.29x
Industry
4.74x
APLT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APLT's financial health
Profit margin
Revenue
$122.0k
Net Income
-$68.6M
Profit Margin
-56,222.1%
APLT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
APLT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$106.6M
Liabilities
$100.7M
Debt to equity
17.09
APLT's short-term assets ($104.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APLT's short-term assets ($104.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APLT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.3M
Investing
$0.0
Financing
$0.0
APLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APLT vs Biotech Stocks
Applied Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.